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Abstract
Beta-adrenergic receptor antagonists (β-blockers) have 
been well established for use in portal hypertension 
for more than three decades. Different Non-selective 
β-blockers like propranolol, nadolol, timolol, atenolol, 
metoprolol and carvedilol have been in clinical practice 
in patients with cirrhosis. Carvedilol has proven 2-4 
times more potent than propranolol as a beta-receptor 
blocker in trials conducted testing its efficacy for 
heart failure. Whether the same effect extends to its 
potency in the reduction of portal venous pressures 
is a topic of on-going debate. The aim of this review 
is to compare the hemodynamic and clinical effects 
of carvedilol with propranolol, and attempt assess 
whether carvedilol can be used instead of propranolol in 
patients with cirrhosis. Carvedilol is a promising agent 
among the beta blockers of recent time that has shown 
significant effects in portal hypertension hemodynamics. 
It has also demonstrated an effective profile in its 
clinical application specifically for the prevention of 
variceal bleeding. Carvedilol has more potent desired 
physiological effects when compared to Propranolol. 
However, it is uncertain at the present juncture whether 
the improvement in hemodynamics also translates into a 
decreased rate of disease progression and complications 
when compared to propranolol. Currently Carvedilol 
shows promise as a therapy for portal hypertension but 
more clinical trials need to be carried out before we can 
consider it as a superior option and a replacement for 
propranolol. 
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Core tip: Carvedilol is a promising agent among the 
beta blockers of recent time that has shown significant 
effects in portal hypertension hemodynamics. For 
primary prophylaxis of variceal bleeding, the effects 
of carvedilol were compared to band ligation in a few 
trials and showed some promise, but there has been no 
comparison with propranolol. Patients not responding to 
propranolol have shown clinical response to carvedilol, 
opening a new window of clinical application. For 
secondary prophylaxis of variceal bleeding, carvedilol 
has been shown to be effective. However no head-to-
head trials comparing propranolol and carvedilol for 
variceal re-bleeding were found in literature. 
Submit a Manuscript: http://www.wjgnet.com/esps/
Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx
DOI: 10.4253/wjge.v7.i5.532
World J Gastrointest Endosc  2015 May 16; 7(5): 532-539
ISSN 1948-5190 (online)
© 2015 Baishideng Publishing Group Inc. All rights reserved.
Abid S, Ali S, Baig MA, Waheed AA. Is it time to replace 
propranolol with carvedilol for portal hypertension? World J 
Gastrointest Endosc 2015; 7(5): 532-539  Available from: URL: 
http://www.wjgnet.com/1948-5190/full/v7/i5/532.htm  DOI: 
http://dx.doi.org/10.4253/wjge.v7.i5.532
INTRODUCTION
Liver cirrhosis remains the 12th leading cause of 
death worldwide according to estimates by the Global 
Burden of Disease Study[1]. Portal hypertension is an 
inevitable consequence of cirrhosis and underlies most 
of its complications like: variceal bleeding, ascites 
and hepatic encephalopathy[2]. Portal hypertension is 
characterised by a pathologic increase in the portal 
pressure gradient (the pressure difference between 
the portal vein and the hepatic veins) y greater than 
5 mmHg. This causes the creation of porto-systemic 
collaterals leading to shunting of portal blood to the 
systemic circulation, bypassing the liver parenchyma. 
It has been shown that therapeutic reduction in portal 
pressure has been shown to improve clinical outcomes 
and reduces the incidence of recurrent haemorrhage, 
ascites, encephalopathy, and death[3-5].
Beta-adrenergic receptor antagonists (β-blockers) 
have been well established for use in portal hyper-
tension for more than three decades. Non-selective 
β-blockers (NSBB) have been widely utilized since 
1980, when the first article on their role in portal 
hypertension was published by Lebrec et al[6]. Portal 
hypertension results from fibrosis or regenerative 
nodules in the liver parenchyma increasing resistance 
to flow and causing mechanical obstruction; contraction 
of sinusoidal and perisinusoidal contractile cells 
(stellate cells and vascular smooth muscle cells) with 
intrahepatic imbalance between vasoconstrictors (such 
as endothelin 1 and angiotensin) and vasodilators; and 
splanchnic vasodilatation in secondary to a relatively 
ischemic liver or extrahepatic excess of NO, with sGC-
PKG signalling and smooth muscle cell relaxation[7] 
(Figure 1).
NSBB have a dual mode of action decrease portal 
pressure, i.e., reduction of cardiac output and splanchnic 
blood flow by β-1 receptor blockade, and β-2 receptor 
blockade, resulting in splanchnic vasoconstriction cau-
sed by unopposed effect of alpha 1 receptors[7]. NSBBs 
have been proven to decrease incidence of bleeding 
(primary prophylaxis) and re-bleeding (secondary 
prophylaxis) from esophageal varices[8-11]. It has been 
demonstrated that they also prevent bleeding from 
portal hypertensive gastropathy and development of 
spontaneous bacterial peritonitis[4,12,13]. Due to their 
widely diverse effects in patients with cirrhosis and 
widespread use, they have been dubbed as “aspirin” in 
clinical hepatology[14].
Different NSBBs like propranolol, nadolol, timolol, 
atenolol, metoprolol and carvedilol have been in 
clinical practice in patients with cirrhosis. Propranolol 
was the first, most widely studied NSBB and mainstr-
eam for treatment of portal hypertension. Carvedilol 
is a nonselective beta-blocker with intrinsic anti-
alpha1-adrenergic activity. It has been a relatively 
newer addition to the NSBBs, in the arena of portal 
hypertension and has demonstrated promising results 
in terms of clinical outcomes.
Carvedilol has proven 2-4 times more potent 
than propranolol as a beta-receptor blocker in trials 
conducted testing its efficacy for heart failure[15]. 
Whether the same effect extends to its potency in 
the reduction of portal venous pressures is a topic of 
ongoing debate.
The aim of this article is to compare the hemody-
namic and clinical effects of carvedilol with propranolol, 
and attempt assess whether carvedilol can be used 
instead of propranolol in patients with cirrhosis.
HEMODYNAMIC EFFECTS
To achieve successful protection against gastrointestinal 
bleeding, the portal pressure [usually measured as 
the hepatic venous pressure gradient (HVPG)] has to 
be decreased to ≤ 12 mmHg or by 20% of baseline 
values[16]. Long-term follow-up of cirrhotic on beta 
blockers has shown that decrease of HVPG of above 
mentioned values results in lesser risk of developing 
variceal bleeding, ascites, spontaneous bacterial peri-
tonitis (SBP), hepatorenal syndrome and hepatic 
encephalopathy[4]. 
Comparison of carvedilol to propranolol for portal 
hypertension was made in a recent systematic review 
with meta-analysis which included five head-to-head 
randomised trials[17-22]. This analysis favored carvedilol 
against propranolol, in terms of: (1) acute effects on 
reduction in HVPG [mean weighted difference in % 
of reduction in hepatic vein pressure gradient; -7.70 
(95%CI: -12.40--3.00)]; (2) long term effects [mean 
weighted difference in % of reduction in hepatic vein 
pressure gradient was -6.81 (95%CI: -11.35--2.26)]; 
and (3) overall effects [(mean weighted difference in 
% of reduction in hepatic vein pressure gradient -7.24 
(95%CI: -10.50--3.97)]. 
Additionally the same metaanalysis showed that 
Carvedilol had a lower relative risk of failure to achieve 
hemodynamic response than propranolol. The number 
of patients who achieved a reduction in HVPG to ≥ 
20% or to ≤ 12 mmHg was reported in 4 of the 5 
studies and was also markedly higher with carvedilol vs 
propranolol (57/94 vs 33/87). However, this favourable 
difference for carvedilol did not reach statistical 
significance. 
Carvedilol caused more reduction in arterial blood 
pressure resulting in orthostatic hypotension as 
compared to propranolol. Propranolol caused a - 6.66 
mmHg (95%CI: -10.17--3.15) mean reduction in 
arterial pressure whereas carvedilol caused a mean 
reduction of -10.40 (95%CI: -13.9--6.9). The reduction 
in mean arterial pressure was found to be significant 
Abid S et al . Carvedilol vs  propranolol for portal hypertension
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with both drugs, but the degree of reduction was in the 
order of one-third more with carvedilol compared to 
propranolol[17] (Figure 2).
Therefore carvedilol has been shown to be superior 
to propranolol in causing of acute, long-term and overall 
reduction of the hepatic venous pressure gradient, i.e., 
portal venous pressure. The proportion of patients who 
demonstrated an adequate response is also higher for 
carvedilol. 
Although the translation of these effects in terms 
of clinical benefit of reduced gastrointestinal bleeding 
events is significant, these changes in hemodynamic 
parameters come at the cost of orthostatic hypotension 
and fluid retention including ascites, with the use of 
carvedilol. However carvedilol can be a safe alternative 
in patients who are not hypotensive. In addition car-
vedilol has achieved significant hemodynamic response 
in more than half of the patients who were resistant to 
propranolol[23].
CLINICAL EFFECTS
Variceal bleeding
Pre-primary prophylaxis: Prevention of development 
of varices in patients with portal hypertension is known 
as pre-primary prophylaxis. Experimental models 
of portal hypertension have shown that B-Blockers 
delay the development of collaterals[24,25]. Escorsell et 
al[26] demonstrated that administration of β-blockers 
(timolol) to patients without varices caused a greater 
reduction in portal pressure than the reduction seen 
in patients with varices[26]. However this effect of use 
of timolol did not translate into prevention of variceal 
formation and variceal hemorrhage in a randomised 
study by Groszmann et al[27] which compared timolol 
with placebo in patients without varices. The study 
by Calés et al[28] using propranolol, for pre-primary 
prophylaxis did not show clinical benefit in terms of 
variceal development. To-date there were no studies 
using carvedilol for pre-primary prophylaxis.
Due to lack of any demonstrated clinical benefits of 
β-blockers in patients with portal hypertension without 
varices and adverse effects of these medications, 
none of the current guidelines (including Baveno V 
consensus[2], AASLD[29], and EASL/AASLD consensus[30]) 
recommend their use for pre-primary prophylaxis.
Primary prophylaxis: NSBB are recommended for 
use in primary prevention of variceal bleeding, as they 
have been associated with decrease in incidence of first 
bleeding episode and mortality benefits[2]. 
A meta-analysis of published randomised controlled 
trials on primary prophylaxis including 1859 patients, 
revealed pooled risk difference of 11% in incidence 
of variceal bleeding with use of propranolol against 
controls[31]. In another meta-analysis, D’Amico et al[32] 
demonstrated that in patients with varices of any size, 
β-blockers reduced the risk of a first bleeding episode 
from 25% to 15% within 2 years. The absolute risk 
difference was 9% (15% vs 24%) as compared to 
placebo. Moreover, the absolute risk reduction in 
mortality was found to be 4% (from 27% to 23%)[32]. 
Another meta-analyses has reported the usage of 
Beta blockers as primary prophylaxis to be associated 
with a 40% reduction in bleeding risk and a trend 
towards improved survival[33]. In a double-blind rando-
mised trial, the Boston-New Haven-Barcelona Portal 
Hypertension Study Group compared propranolol with 
placebo for primary prophylaxis. There was significant 
difference in incidence of bleeding between the study 
groups favouring propranolol (incidence of bleeding 
4% vs 22%; P ≤ 0.01) during a mean follow-up of 16 
mo. However there was no difference in mortality rates 
between the two groups[34].
Propranolol has been compared to esophageal 
band ligation (EBL) in terms of bleeding prevention 
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Figure 1  Pathogenesis of portal hypertension.
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of HVPG in patients failing to respond to propranolol, 
thus leading to lesser bleeding episodes in this group 
of patients. Bleeding rates followed up for 2 years were 
11% with propranolol vs 5% with carvedilol and 25% 
with EBL (P = 0.0429)[23]. We did not find any studies 
comparing propranolol with carvedilol head-to-head for 
primary prevention. 
Secondary prophylaxis: Secondary prophylaxis is 
prevention of recurrence after index variceal bleeding 
episode. The 1-year mortality after an episode of 
variceal bleeding is 40%[11]. Variceal bleeding recurs in 
60% at 1-year with 6-wk mortality of 20% for every 
re-bleeding episode[2]. NSBBs have been widely used 
for prevention of re-bleeding and have been shown 
to decrease the rate of re-bleeding from varices to 
42%, as compared to 63% in controls in several meta-
analyses[32]. In addition these agents decrease overall 
mortality from 27% to 20%, and bleeding related 
mortality[40].
Carvedilol was compared with combination of nad-
olol and isosorbide-5-mononitrate in a randomized 
controlled trial in patients who previously had variceal 
bleeding. This study demonstrated that after a follow-
up of 30 mo there was no significant difference in 
incidence of recurrent upper gastrointestinal bleeding 
between carvedilol and combination groups (62% vs 
61%; P = 0.90). There was no significant difference 
between the Rate of recurrence of variceal bleeding 
between the carvedilol and combination groups (51% 
vs 43%; P = 0.46)[41]. Interim analysis of a multicentre 
randomised controlled study comparing carvedilol with 
endoscopic band ligation for secondary prevention 
of variceal bleeding, demonstrated no significant 
and mortality reduction in patients with cirrhosis in 
several randomised controlled trials. A meta-analysis of 
sixteen randomised controlled trials found EBL causing 
significant reduction of the risk of first variceal bleeding 
compared to propranolol (relative risk difference 9.2%, 
95%CI: 5.2%-13.1%, and POR 0.5, 95%CI: 0.37–
0.68). However there was no statistically significant 
difference in Mortality between the two groups (POR 
0.94, 95%CI: 0.70-1.28). On average, 3 endoscopic 
sessions were required to eradicate varices and at least 
33 endoscopic procedures were needed to prevent one 
bleeding episode as compared with NSBBs[35]. However 
as NSBB are cheap, as haemodynamic monitoring is 
not required[36].
In a randomized control trial, Carvedilol has been 
compared with EBL and showed a significantly lower 
rate of first variceal bleeding (with minor adverse 
effects) in patients taking carvedilol 12.5 mg daily 
compared with EBL (10% vs 23%, HR = 0.41, 95%CI: 
0.19-0.96)[37]. The lowest dose of carvedilol tested 
in this trial was 12.5 mg, which is known to cause 
a smaller reduction in HVPG than to actually cause 
prevention of first bleeding episode. So the results of 
this study need to be interpreted after considering its 
limitations[38]. 
Another randomised controlled trial by Shah et 
al[39] reported that both EBL and carvedilol groups had 
comparable variceal bleeding rates (8.5% vs 6.9%), 
bleeding related mortality (4.6% vs 4.9%) and overall 
mortality (12.8% vs 19.5%) respectively[39]. Although 
the study was underpowered, the authors suspect that 
carvedilol is not superior to EBL for primary prophylaxis 
of varices. 
Use of carvedilol has been found to cause reduction 
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Figure 2  Hemodynamic effect of carvedilol compared to propranolol (Data from ref.[19]). HVPG: Hepatic venous pressure gradient.
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propranolol alone[43].
Propranolol retains its place as the most widely used 
and studied drug for secondary prophylaxis with clear 
benefits as compared to placebo and combination with 
EBL. The evidence for carvedilol in variceal rebleeding 
recurrence is minimal but promising.
Portal gastropathy
Described as mosaic, snake-skin-like appearance of 
gastric mucosa with or without red punctuate erythema, 
portal hypertensive gastropathy (PHG) is estimated to 
be present in up to 80% of cirrhotic patients[44]. PHG 
can cause acute bleeding rarely with an incidence of 3% 
in three years, and in 2.5%-30% patients it may result 
in chronic insidious bleeding[45,46]. 
NSBBs have been shown to lower the incidence of 
bleeding in acute and chronic forms of haemorrhage 
from PHG. One of the earliest randomised controlled 
trials using propranolol showed lower haemorrhage 
rates, increase in haemoglobin level and an apparent 
improvement in the endoscopic appearance of the 
lesion when compared to placebo[47]. Pérez-Ayuso et 
al[12], in a randomised trial of used propranolol against 
no therapy in patients for secondary prophylaxis of 
bleeding from PHG. The study demonstrated higher 
number of patients remaining free of bleeding with 
propranolol in acute (85% vs 20%) and chronic setting 
(69% vs 30% at 30 mo). On multivariate analysis, the 
sole independent predictor of recurrent haemorrhage 
was the absence of propranolol[12]. 
difference between the groups in re-bleeding rates 
(37.5% vs 29%; P = 0.72). However the patients in 
carvedilol group had lower 1-year mortality rates as 
compared to EBL group (25% vs 51.6%; P = 0.058)[42].
The pioneer trial by Pagliaro et al[8] demonstrated 
that propranolol was effective in decreasing the in-
cidence of variceal re-bleeding when compared to 
controls. A comprehensive meta-analysis of 12 rand-
omised controlled trials for secondary prophylaxis 
of variceal bleeding showed that, use of β-blockers 
(11 using propranolol) was associated with increase 
in mean percentage of patients with no re-bleeding 
(21% mean improvement rate, 95%CI: 10%-32%, 
P < 0.001), the mean percentage of patients with no 
variceal re-bleeding (20% mean improvement rate, 
95%CI: 11%-28%, P < 0.001), the mean survival rate 
(5.4% mean improvement rate, 95%CI: 0%-11%, P < 
0.05, RR = 1.27), the mean percentage of patients free 
of bleeding death (7.4%, 95%CI: 2%-13%, P < 0.01, 
RR = 1.50)[40]. 
Baveno V consensus guidelines recommend a 
combination of β-blockers and variceal band ligation 
as the preferred therapy for secondary prophylaxis 
because it results in lower re-bleeding rates compared 
to either therapy alone[2]. Ahmad et al[43] compared 
combination of EBL and propranolol against propranolol 
for secondary prevention and found no statistical 
difference in re-bleeding (22% vs 38%) and mortality 
rates (23% vs 19%) between the groups. However 
the incidence of re-bleeding was higher in patients on 
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Figure 3  Current evidence about carvedilol and propranolol as prophylactic therapy.
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to propranolol (Figure 3).
There have been no clinical trials comparing 
carvedilol and propranolol for pre-primary prophylaxis. 
For Primary prophylaxis, the effects of Carvedilol have 
been compared to Endoscopic band ligation in a few 
trials and show some promise, but there has been no 
head to head comparison with propranolol. However, 
patients not responding to propranolol have shown 
clinical response to Carvedilol, opening a new window 
of clinical application.
For secondary prophylaxis, carvedilol has been 
compared to Beta blockers other than propranolol and 
Endoscopic Band Ligation, and seems to be equally 
effective. However, the most effective therapy to date 
remains a combination of Endoscopic Band Ligation, 
and no head to head trials have been conducted 
comparing carvedilol with propranolol. Similarly, there 
have been no trials exploring the role of carvedilol 
in portal hypertensive gastropathy and spontaneous 
bacterial peritonitis.
Thus, currently Carvedilol shows promise as a 
therapy for portal hypertension but more clinical trials 
need to be carried out before we can consider it as a 
superior option and a replacement for propranolol. 
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Although the use of β-blockers for PHG is wide-
spread, based upon current evidence strong recom-
mendations can’t be made for NSBB for this indication. 
We also did not find any studies using carvedilol to 
control bleeding from portal gastropathy. 
Spontaneous bacterial peritonitis
NSBBs have been shown to have preventive effect 
on development of spontaneous bacterial peritonitis 
in a meta-analysis by Senzolo et al[13]. This analysis 
included three randomised controlled trials and 
two retrospective studies all using propranolol for 
prophylaxis of variceal bleeding, with respect to the 
incidence of SBP. Statistically significant difference of 
12.1% (P < 0.001) was found in favour of propranolol 
in prevention of SBP. 
A recently published thorough retrospective analysis 
of data from 607 patients with cirrhosis by Mandorfer 
et al[48] demonstrated no difference in incidence of 
SBP between NSBB users and patients who did not. 
Occurrence rates of SBP were similar between patients 
with and without NSBB treatment. However, NSBB 
use was associated with higher transplant-free survival 
in patients without SBP and reduced hospitalization 
rates[48]. 
In contrast, Mandorfer et al[48] demonstrated that 
in patients who have developed SBP, NSBB were 
associated with hemodynamic compromise and dec-
reased blood pressures, reduced transplant free 
survival, increased hospitalization rates, and incre-
ased incidence of the hepatorenal syndrome and 
acute kidney injury. In another study, using a NSBB 
(propranolol) in patients with refractory ascites was 
found to reduce 1-year survival against those not 
using this drug (median survival: 5 mo vs 20 mo res-
pectively)[49]. These results advocate against the use of 
NSBB in patients with advanced cirrhosis with ascites 
and SBP.
To conclude, the current evidence is variable about 
the role of NSBB in decreasing the incidence of SBP. 
However they can increase transplant-free survival in 
patients without SBP. In cases of advanced cirrhosis 
with ascites and the patients who have developed 
SBP, their use proves detrimental causing higher rates 
of hemodynamic compromise, time of hospitalization 
and risks of renal dysfunction. All the studies on 
NSBB use for SBP have used propranolol. We did not 
find any study about the use of carvedilol in patients 
with advanced cirrhosis and SBP, nor a head-to-head 
comparison of propranolol and carvedilol in this regard.
CONCLUSION
After reviewing the existing literature, it seems that 
Carvedilol has more potent desired physiological effects 
when compared to Propranolol. However, it is uncertain 
at the present juncture whether the improvement in 
hemodynamics also translates into a decreased rate of 
disease progression and complications when compared 
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